The study met the primary objective with 67% of patients having CD4+ cells >100/μl by Day +120 with acceptable rates of GvHD (Grade 2–3 11%, no Grade 4 GvHD, and 16% chronic). This evidence concerns the gene CD4 and graft versus host disease.